Literature DB >> 16050476

[Synergetic responses after administration of interleukin-2 and Interferon-alpha combined with gamma knife radiosurgery in a patient with multiple lung and brain metastases: a case report].

Toshihiko Takada1, Yoshiteru Yamada, Masahiro Uno, Hisao Komeda, Yoshinori Fujimoto.   

Abstract

A 51-year-old man with left renal tumor and multiple lung metastases was admitted to our hospital for treatment. Left nephrectomy was performed, and pathological diagnosis was renal cell carcinoma (clear cell carcinoma, G2, pT3a). Initially, Interferon-alpha (IFN-alpha) therapy was started for lung metastases. About 40 days after surgery, head magnetic resonance imaging revealed brain metastases, and therefore gamma knife radiosurgery(GKS) was performed. Since chest computed tomography showed no change in lung metastases, we tried a combination of interleukin-2 (IL-2) and IFN-alpha therapy to elininate those metastases. As a result, neither lung nor brain metastases could be detected at the 4th month follow-up examination. At 5 months after the IL-2 and IFN-alpha therapy, the patient attempted suicide. Therefore, the IL-2 and IFN-alpha therapy was stopped and an antidepressant was prescribed. Now 11 months after withdrawal of the IL-2 and IFN-alpha, the patient's mental condition remains stable. No recurrence of the cancer has been detected by CT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16050476

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  1 in total

1.  Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System.

Authors:  Eric K Nguyen; Aly Khan A Lalani; Sunita Ghosh; Naveen S Basappa; Anil Kapoor; Aaron R Hansen; Christian Kollmannsberger; Daniel Heng; Lori A Wood; Vincent Castonguay; Denis Soulières; Eric Winquist; Christina Canil; Jeffrey Graham; Georg A Bjarnason; Rodney H Breau; Frédéric Pouliot; Anand Swaminath
Journal:  Adv Radiat Oncol       Date:  2022-01-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.